



# NORRIS

## MEDICINES LIMITED



**Factory** : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230MH1990PLC058071

### ANNEXURE I

#### Part I - Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31/12/2015

(Rs. In Lacs)

| Particulars   | 3 months ended 31/12/2015 | Preceding 3 months ended 30/09/2015 | Corresponding 3 months ended in the previous year 31/12/2014 | Year to date figure for current period 31/12/2015 | Year to date figures for the previous year ended 31/12/2014 | Previous year ended 31/03/2015 |
|---|---------------------------|-------------------------------------|--|---|---|--------------------------------|
|   | (Unaudited)               | (Unaudited)                         | (Unaudited)  | (Unaudited)                                       | (Unaudited)   | (Audited)                      |
| 1. Income from Operations   |                           |                                     |  |   |   |                                |
| (a) Net Sales/ Income from Operations (Net of Excise Duty)  | 447.86                    | 558.68                              | 525.48   | 1369.90   | 1424.07   | 1867.79                        |
| (b) Other Operating Income  | 0.00                      | 0.00                                | 0.00   | 9.32  | 0.00  | 12.88                          |
| <b>Total Income from Operations (Net)</b>   | <b>447.86</b>             | <b>558.68</b>                       | <b>525.48</b>  | <b>1379.22</b>                                    | <b>1424.07</b>  | <b>1880.67</b>                 |
| 2. Expenses   |                           |                                     |  |   |   |                                |
| (a) Cost of materials consumed  | 249.92                    | 272.55                              | 225.64   | 725.25  | 724.40  | 913.34                         |
| (b) Purchase of stock in trade  | 0.00                      | 0.00                                | 0.00   | 0.00  | 0.00  | 0.00                           |
| (c) Change in inventories of finished goods work in progress and stock-in-trade   | -57.89                    | 5.90                                | 62.97  | -100.82   | 1.36  | -1.33                          |
| (d) Employee benefits expense   | 132.24                    | 127.10                              | 108.30   | 359.90  | 298.92  | 408.36                         |
| (e) Depreciation and amortisation expense   | 31.47                     | 31.47                               | 31.54  | 94.40   | 93.05   | 131.23                         |
| (f) Other Expense (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately) |                           |                                     |  |   |   |                                |
|   | 93.80                     | 93.57                               | 87.54  | 274.56  | 278.10  | 376.60                         |
| <b>Total Expenses</b>   | <b>449.54</b>             | <b>530.59</b>                       | <b>515.99</b>  | <b>1353.29</b>                                    | <b>1395.83</b>  | <b>1828.20</b>                 |
| 3. Profit / (Loss) from operations before other income finance costs and exceptional items (1-2)                          | -1.68                     | 28.09                               | 9.49   | 25.93   | 28.24   | 52.47                          |
| 4. Other Income   | 2.73                      | 1.94                                | 0.16   | 9.28  | 0.41  | 2.03                           |
| 5. Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)                            | 1.05                      | 30.03                               | 9.65   | 35.21   | 28.65   | 54.50                          |
| 6. Finance Costs  | 27.42                     | 15.83                               | 14.42  | 56.40   | 39.06   | 53.81                          |
| 7. Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)                      | -26.37                    | 14.20                               | -4.77  | -21.19  | -10.41  | 0.69                           |
| 8. Exceptional items  | 0.00                      | 0.00                                | 0.00   | 0.00  | 0.00  | 0.00                           |
| 9. Profit / (Loss) from ordinary activities before tax (7 ± 8)  | -26.37                    | 14.20                               | -4.77  | -21.19  | -10.41  | 0.69                           |
| 10. Tax Expense   | 0.00                      | 0.00                                | 0.00   | 0.00  | 0.00  | 105.04                         |
| 11. Net Profit / (Loss) from ordinary activities after tax (9 ± 10)   | -26.37                    | 14.20                               | -4.77  | -21.19  | -10.41  | -104.35                        |
| 12. Extraordinary Items (Net of tax expense Rs. _____ Lakhs)  | 0.00                      | 0.00                                | 0.00   | 0.00  | 0.00  | 0.00                           |
| 13. Net Profit / (Loss) for the period (11 ± 12)  | -26.37                    | 14.20                               | -4.77  | -21.19  | -10.41  | -104.35                        |
| 14. Share of Profit / (Loss) of Associates*   | 0.00                      | 0.00                                | 0.00   | 0.00  | 0.00  | 0.00                           |
| 15. Minority Interest*  | 0.00                      | 0.00                                | 0.00   | 0.00  | 0.00  | 0.00                           |



# NORRIS

## MEDICINES LIMITED



**Factory** : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230MH1990PLC058071

|  |        |        |        |        |        |         |
|--|--------|--------|--------|--------|--------|---------|
| 16. Net Profit / (Loss) after taxes, minority interest share of Profit / (Loss) of associates (13 ± 14 ± 15) | -26.37 | 14.20  | -4.77  | -21.19 | -10.41 | -104.35 |
| 17. Paid-up Equity Share Capital (face value of the share shall be indicated)                                | 992.58 | 992.58 | 992.58 | 992.58 | 992.58 | 992.58  |
| 18. Reserve excluding revaluation reserves as per balance sheet of previous accounting year                  | 0.00   | 0.00   | 0.00   | 0.00   | 0.00   | 0.00    |
| 19.i. Earning per share (before extraordinary items) (of----/-each) (not Annualised):                        |        |        |        |        |        |         |
| (a) Basic  | -0.26  | 0.14   | -0.05  | -0.21  | -0.10  | -1.04   |
| (b) Diluted  | -0.26  | 0.14   | -0.05  | -0.21  | -0.10  | -1.04   |
| 19. ii. Earning per share (after extraordinary items) (of----/-each) (not Annualised):                       |        |        |        |        |        |         |
| (a) Basic  | -0.26  | 0.14   | -0.05  | -0.21  | -0.10  | -1.04   |
| (b) Diluted  | -0.26  | 0.14   | -0.05  | -0.21  | -0.10  | -1.04   |

**Notes:**

1. The Audit Committee has reviewed the above results and Board of Directors has approved the above results and its release at their respective meetings held on 14th February, 2016. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
2. There are no separate reportable segments.
3. We have not pledged our shares in any Banks or in any other Financial Institution.
4. Figures of previous Quarters/Years have been regrouped and reclassified wherever necessary.

For, Norris Medicines Limited

Vimal D. Shah  
Managing Director

Date : 14.02.2016  
Place : Ankleshwar



**Review Report to the Board of Directors**  
**Norris Medicines Limited**  
**Ankleshwar.**

We have reviewed the accompanying statement of unaudited financial results of **Norris Medicines Limited** ("the company") for the period ended 31<sup>st</sup> December, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : BHARUCH

Date : 14<sup>th</sup> February, 2016

232, Rangoli Complex,  
Station Road,  
Bharuch – 392 001  
Gujarat.

For, **MINU MODI & CO.**

Chartered Accountants

**CA MINU MODI**

Proprietor

M. No. 100289

(Firm Reg. No. 119948W)

